Skip to Content

Frequency Therapeutics, Inc.

Merger

  • Date:
  • 7/17/2023
  • Company Name:
  • Frequency Therapeutics, Inc.
  • Stock Symbol:
  • FREQ
  • Company Name - Buyer:
  • Korro Bio, Inc.
  • Status:
  • Investigating
  • Merger Announcement Date:
  • 7/7/2023

Case Finder

Locate any case using the tools below.

NEW YORK, July 17, 2023 – Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the officers or directors of Frequency Therapeutics, Inc. (NASDAQ: FREQ) (“Frequency Therapeutics”) breached their fiduciary duties or violated the federal securities laws in connection with the company’s acquisition by Korro Bio, Inc. ("Korro Bio").

On July 14, 2023, Frequency Therapeutics announced that it had entered into an agreement to be acquired by Korro Bio in an all-stock deal. Pursuant to the merger agreement, Korro Bio shareholders will receive newly issued shares of Frequency Therapeutics common stock pursuant to a formula set forth in the merger agreement. The deal is expected to close in the fourth quarter of 2023.

Bragar Eagel & Squire is concerned that Frequency Therapeutics' board of directors oversaw an unfair process and ultimately agreed to an inadequate merger agreement. Accordingly, the firm is investigating all relevant aspects of the deal and is committed to securing the best result possible for Frequency Therapeutics' stockholders.
The individual or institution below (“Plaintiff”) has reviewed and agrees to the Bragar Eagel & Squire, P.C. (“BESPC”) retainer agreement and authorizes BESPC to prosecute an action on Plaintiff’s behalf under the federal securities laws or applicable state laws to recover damages on behalf of investors in Frequency Therapeutics. BESPC will prosecute the action on a full contingency basis and will forward all costs and expenses.
 

Case Finder

Locate any case using the tools below.

You may share a link to this page on any of the sites listed below or send link via email: